Abstract
In this issue of Cancer Cell, Yang etal. report the third in a series of phase III trials that demonstrates the survival benefit of combining a PD-1 inhibitor with chemotherapy in nasopharyngeal cancer. A gene expression analysis identifies "hot" and "cold" tumor signatures with prognostic and predictive significance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have